Phase 3 N=628 Randomized Prevention

Preventing Non-communicable Diseases in Guatemala Through Sugary Drink Reduction

Food Preferences

Bottom Line

View on ClinicalTrials.gov: NCT04022694 ↗

Enrolled (actual)

628

Serious AEs

0.0%

Results posted

Mar 2021

Primary outcome: Primary: Volume of SSBs Per Transaction — 116.2; 89.8; 115.3; 103.4 mL of Sugar Sweetened Beverages purchase

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Exposure to beverage health information (Behavioral); Exposure to beverage calorie information (Behavioral)
Age: Pediatric, Adult · 12+ yrs
Sex: All
Sponsor: University of Pennsylvania
Primary completion: Aug 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Volume of SSBs Per Transaction	116.2; 89.8; 115.3; 103.4	—
PRIMARY Beverage Calories Per Transaction	45.1; 35.9; 41.2; 39.0	—
SECONDARY Total Calories Per Transaction	290.8; 338.5; 287.5; 332.0	—

Summary

Sugar-sweetened beverages are a significant contributor to adult and childhood obesity in Guatemala. Policies to place health warning labels on sugar-sweetened beverages are being pursued, but there is little empirical data on how such labels influence people. The primary aim of this study is to test the association between sugar-sweetened beverage (SSB) warning posters compared to control posters and change in SSBs purchased compared to baseline by adolescents shopping at school cafeterias in Guatemala City, Guatemala. The hypothesis is that posters with information warning people of the health harms associated with overconsuming SSBs and promoting low sugar beverages will be associated with greater reductions in SSB purchases compared to a control poster.

Eligibility Criteria

Inclusion Criteria

Between 12 and 18 years old
Made a food or beverage purchase
Has permission from parent or caregiver to participate
Has not yet completed the purchase assessment

Exclusion Criteria

Under 12 or over 18 years old
Did not make a food or beverage purchase
Parent or caregiver refused to give child permission to participate
Already participated in the purchase assessment

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04022694). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.